All In Biotech

Drug Trial Radar · NCT01285466

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

110

Actual

Start

Jan 2011

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.

Conditions

  • Metastatic or Locally Advanced Solid Tumors

Interventions

  • BEZ235 + paclitaxelDrug

  • BKM120 + paclitaxelDrug

  • BEZ235 + paclitaxel + trastuzumabDrug

  • BKM120 + paclitaxel + trastuzumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose limiting toxicities during the first cycle of treatment.Time frame: First treatment cycle (4 weeks)

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Chur, Switzerland

  • Novartis Investigative Site

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.